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Exposures to per-and polyfluoroalkyl 
substances (PFAS): Reducing potential 
risks to reproductive and children's health

PFAS Basics
What other potential exposure points and 





Health Effects (ATSDR, 2021)
Blood testing for PFAS
Blood Testing for PFAS
• Human exposure to PFAS is ubiquitous in both U.S. and globally 
• No specific biomarkers of clinical effects caused by PFAS
• Presence of PFAS in blood confirms past exposure (distant or recent), 
but does not indicate development of adverse health effects and does not 
identify source of exposure
Agency for Toxic Substances and Disease Registry (ATSDR). 2018. Toxicological profile for Perfluoroalkyls. (Draft for 
Public Comment). Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service. 
When is biomonitoring for PFAS exposure helpful?
 Identifying baseline 
levels
 Confirming exposures 
 Identifying the 
prevalence of people 
above known toxicity 
levels
 Identifying temporal 
trends
 Assessing the 
effectiveness of public 
health efforts for 
reducing chemical 
exposures
 Informing occupational 
safety measures needed 
to prevent future 
exposures 
 Setting priorities for 
future research efforts 
What Serum PFAS Levels 
Cannot Do Alone
What Serum PFAS Levels CANNOT Do Alone
 Provide specific 
information about 
the sources of the 
PFAS
 Provide information 
about the frequency, 
duration, or pathway 
of exposure.
 Predict whether the 
presence of PFAS in 







• The best strategy is prevention of exposure
• Therapies intended to reduce body burden by enhancing elimination 
of PFAS are not recommended
• Mitigating risk of disease involves reducing PFAS exposure and 
minimizing other disease risk factors
Clinical Implications
 Perform routine diagnostic/screening tests 
based on a thorough history, physical exam, 
and assessment – Clinician should use clinical 
judgement to determine appropriate uses of 
diagnostic tests and screenings.
 Currently, no specific testing or screening is 
recommended based on PFAS levels
 Cannot connect specific health problems to 
PFAS 
 Repeat PFAS testing not medically indicated
Clinical Implications 
Reducing Exposures to PFAS
Reducing Exposures to PFAS 
Drinking water     
filters 
• Granular activated 
carbon (AC) 





 Local fish advisories
 Consumer products
 Garden Soil
Key Messages for Providers
1. Most people in the United States have some PFAS in their body. 
2. Reducing exposures to PFAS is the most important step for families 
with concerns about PFAS. A home water filtration system can reduce 
the contaminant levels in drinking water. Reducing exposures from 
certain consumer products is also advisable. 
3.     If your patient presents with health concerns that might be 
associated with PFAS exposure, it is appropriate to discuss these 
concerns and perform a thorough exposure history and a physical exam 
relative to any symptoms reported. 
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